Reported about 6 hours ago
aTyr Pharma, a small-cap biotech company focused on treating pulmonary sarcoidosis, is on the verge of a significant breakthrough with its leading candidate, efzofitimod, awaiting phase 3 clinical trial results. While the company has shown a 40% increase in stock value this year and could tap into a large market of potential patients, investing in aTyr Pharma remains risky until the efficacy of efzofitimod is confirmed. Investors are advised to wait for definitive trial outcomes before making investment decisions.
Source: YAHOO